Aerosol formulation for the inhalation of beta-agonists
First Claim
Patent Images
1. ) A pharmaceutical formulation comprising as sole active substance one or more compounds of formula 1 wherein R1 denotes hydrogen, C1-C4-alkyl, C1-C4-alkoxy or halogen;
- R2 denotes hydrogen, C1-C4-alkyl, C1-C4-alkoxy or halogen;
R3 denotes hydrogen, c1-C4-alkyl, c1-C4-alkoxy, halogen, oh, —
O-C1-C4-alkylene-COOH or —
O-C1-C4-alkylene-COO-C1-C4-alkyl, X−
denotes an anion with a single negative charge, preferably an anion with a single negative charge selected from the group consisting of chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate, optionally in the form of their tautomers, enantiomers, mixtures of enantiomers, racemates or solvates, at least one pharmacologically acceptable acid, optionally other pharmacologically acceptable excipients and/or complexing agents and, as solvent, water, ethanol or a mixture of water and ethanol.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to a propellant-free aerosol formulation which [contains] one or more compounds of general formula 1
wherein the groups R1, R2, R3 and X− may have the meanings given in the claims and specification, for inhalation.
-
Citations
18 Claims
-
1. ) A pharmaceutical formulation comprising as sole active substance one or more compounds of formula 1
wherein R1 denotes hydrogen, C1-C4-alkyl, C1-C4-alkoxy or halogen; -
R2 denotes hydrogen, C1-C4-alkyl, C1-C4-alkoxy or halogen;
R3 denotes hydrogen, c1-C4-alkyl, c1-C4-alkoxy, halogen, oh, —
O-C1-C4-alkylene-COOH or —
O-C1-C4-alkylene-COO-C1-C4-alkyl,X−
denotes an anion with a single negative charge, preferably an anion with a single negative charge selected from the group consisting of chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate,optionally in the form of their tautomers, enantiomers, mixtures of enantiomers, racemates or solvates, at least one pharmacologically acceptable acid, optionally other pharmacologically acceptable excipients and/or complexing agents and, as solvent, water, ethanol or a mixture of water and ethanol. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
-
Specification